Inventory

9 Months Ended

Dec. 31, 2018

Inventory Disclosure [Abstract]

Inventory

NOTE 9 – INVENTORY

On November 1, 2018 the Company and its independent contract quality control organization discovered a possible contamination in vials produced from lots #2 and #3 of three separate lots that were included in inventory. No vials derived from lots #2 and #3 have been distributed to customers. The identified lots and vials were produced by the Company’s former third-party contract manufacturer. On November 5, 2018 we issued a formal Notice of Product Quarantine and Product Monitoring Period whereby we asked for any unused vials to be quarantined while the Company’s scientific team and third-party contract testing organization analyzed whether lot #1 also included contamination. No evidence of contamination of vials distributed from lot #1 has been identified to date. Approximately $47,500 in inventory has been written off in relation to this event to research and development expense attributed to the loss of lots #2 and #3. Approximately $10,000 in inventory has been written off in relation to additional third-party product testing of lot #1.

The $48,162 of total inventory is broken out as follows:

	December 31, 2018
Finished Goods	$	35,666
Work in Process		-0-
Manufacturing Supplies		3,128
Raw Materials		9,368
Total Inventory	$	48,162